EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Targeting PI3K-gamma in myeloid driven tumour immune suppression: a systematic review and meta-analysis of the preclinical literature

Haonan Xu, Shannon Nicole Russell, Katherine Steiner, Eric O'Neill, Keaton Ian Jones

Cancer Immunology, Immunotherapy · 2024

DOI: 10.1007/s00262-024-03779-2 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Haonan Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Class Ib Phosphatidylinositol 3-Kinase, Myeloid Cells, Neoplasms, Phosphoinositide-3 Kinase Inhibitors. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The intricate interplay between immune and stromal cells within the tumour microenvironment (TME) significantly influences tumour progression. Myeloid cells, including tumour-associated macrophages (TAMs), neutrophils (TANs), and myeloid-derived suppressor cells (MDSCs), contribute to immune suppression in the TME (Nakamura and Smyth in Cell Mol Immunol 17(1):1–12 (2020). https://doi.org/10.1038/s41423-019-0306-1 ; DeNardo and Ruffell in Nat Rev Immunol 19(6):369–382 (2019). https://doi.org/10.1038/s41577-019-0127-6 ). This poses a significant challenge for novel immunotherapeutics that rely on host immunity to exert their effect. This systematic review explores the preclinical evidence surrounding the inhibition of phosphoinositide 3-kinase gamma (PI3Kγ) as a strategy to reverse myeloid-driven immune suppression in solid tumours. EMBASE, MEDLINE, and PubMed databases were searched on 6 October 2022 using keyword and subject heading terms to capture relevant studies. The studies, focusing on PI3Kγ inhibition in animal models, were subjected to predefined inclusion and exclusion criteria. Extracted data included tumour growth kinetics, survival endpoints, and immunological responses which were meta-analysed. PRISMA and MOOSE guidelines were followed. A total of 36 studies covering 73 animal models were included in the review and meta-analysis. Tumour models covered breast, colorectal, lung, skin, pancreas, brain, liver, prostate, head and neck, soft tissue, gastric, and oral cancer. The predominant PI3Kγ inhibitors were IPI-549 and TG100-115, demonstrating favourable specificity for the gamma isoform. Combination therapies, often involving chemotherapy, radiotherapy, immune checkpoint inhibitors, biological agents, or vaccines, were explored in 81% of studies. Analysis of tumour growth kinetics revealed a statistically significant though heterogeneous response to PI3Kγ monotherapy, whereas the tumour growth in combination treated groups were more consistently reduced. Survival analysis showed a pronounced increase in median overall survival with combination therapy. This systematic review provides a comprehensive analysis of preclinical studies investigating PI3Kγ inhibition in myeloid-driven tumour immune suppression. The identified studies underscore the potential of PI3Kγ inhibition in reshaping the TME by modulating myeloid cell functions. The combination of PI3Kγ inhibition with other therapeutic modalities demonstrated enhanced antitumour effects, suggesting a synergistic approach to overcome immune suppression. These findings support the potential of PI3Kγ-targeted therapies, particularly in combination regimens, as a promising avenue for future clinical exploration in diverse solid tumour types. Graphical abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Class Ib Phosphatidylinositol 3-KinaseMyeloid CellsNeoplasmsPhosphoinositide-3 Kinase InhibitorsTumor MicroenvironmentAnimalsHumansImmunotherapyMyeloid-Derived Suppressor Cells

Stichwörter der Autor:innen

MacrophageMeta-analysisPI3K-gammaRepolarisationTumour

Substanzen

Class Ib Phosphatidylinositol 3-KinasePhosphoinositide-3 Kinase InhibitorsPIK3CG protein, human

Autor:innen und Institutionen

  • Department of Oncology, University of Oxford, Oxford, UK.
  • Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
  • Bodleian Health Care Libraries, University of Oxford, Oxford, UK.
  • Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK. keaton.jones@nds.ox.ac.uk.

Zitieren

APA

Xu, H., Russell, S. N., Steiner, K., O'Neill, E., & Jones, K. I. (2024). Targeting PI3K-gamma in myeloid driven tumour immune suppression: a systematic review and meta-analysis of the preclinical literature. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03779-2

Vancouver

Xu H, Russell SN, Steiner K, O'Neill E, Jones KI. Targeting PI3K-gamma in myeloid driven tumour immune suppression: a systematic review and meta-analysis of the preclinical literature. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03779-2

BibTeX
@article{Xu2024,
  author = {Xu, Haonan and Russell, Shannon Nicole and Steiner, Katherine and O'Neill, Eric and Jones, Keaton Ian},
  title = {Targeting PI3K-gamma in myeloid driven tumour immune suppression: a systematic review and meta-analysis of the preclinical literature},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  doi = {10.1007/s00262-024-03779-2}
}
Kostenlos starten →